دورية أكاديمية
أعرض في EDS

Cost effectiveness analysis of a fixed dose combination pill for primary prevention of cardiovascular disease from an individual participant data meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Cost effectiveness analysis of a fixed dose combination pill for primary prevention of cardiovascular disease from an individual participant data meta-analysis.
المؤلفون: Lamy A; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; Department of Surgery, McMaster University, Hamilton, Ontario, Canada., Tong W; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada., Joseph P; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; Department of Medicine, McMaster University, Hamilton, ON, Canada., Gao P; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada., Huffman MD; The George Institute for Global Health, University of New South Wales, Sydney, Australia.; Cardiovascular Division and Global Health Center, Washington University in St. Louis, St. Louis, USA., Roshandel G; Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran., Malekzadeh R; Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Lopez-Jaramillo P; Masira Research Institute, Medical School, Universidad de Santander, Bucaramanga, Colombia., Pais P; St. John's Research Institute, Bangalore, India., Xavier D; St. John's Medical College, Bangalore, India., Avezum A; International Research Center, Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil., Dans AL; University of the Philippines, Manila, Philippines., Gamra H; Fattouma Bourguiba Hospital and University of Monastir, Monastir, Tunisia., Yusuf S; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; Department of Medicine, McMaster University, Hamilton, ON, Canada.
المصدر: EClinicalMedicine [EClinicalMedicine] 2024 May 27; Vol. 73, pp. 102651. Date of Electronic Publication: 2024 May 27 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: The Lancet Country of Publication: England NLM ID: 101733727 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5370 (Electronic) Linking ISSN: 25895370 NLM ISO Abbreviation: EClinicalMedicine Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : The Lancet, [2018]-
مستخلص: Background: Cardiovascular disease (CVD) continues to impart a large burden on the global population, especially in lower income countries where affordability limits the use of cardiovascular medicines. A fixed dose combination strategy of at least 2 blood pressure lowering medications and a statin with aspirin in a single pill has been shown to reduce the risk of incident CVD by 38% in primary prevention in a recent meta-analysis. We report the in-trial (median follow-up: 5 years) cost-effectiveness of a fixed dose combination (FDC) pill in different income groups based on data from that meta-analysis.
Methods: Countries were categorized using World Bank economic groups: Lower Middle Income Countries (LMIC), Upper Middle Income Countries (UMIC) and High Income Countries (HIC). Country specific costs were obtained for hospitalized events, procedures, and non-study medications (2020 USD). FDC price was based on the cheapest equivalent substitute (CES) for each component.
Findings: For the CES-FDC pill versus control the difference in cost was $346 (95% CI: $294-$398) per participant in Lower Middle Income Countries, $838 (95% CI: $781-$895) in Upper Middle Income Countries and $42 (95% CI: -$155 to $239) (cost-neutral) in High Income Countries. During the study period the CES-FDC pill was associated with incremental gain in quality-adjusted life years of 0.06 (95% CI: 0.04-0.08) resulting in an incremental cost-effectiveness ratio (ICER) of $5767 (95% CI: 5735-$5799), $13,937 (95% CI: $13,893-$14,041) and $700 (95% CI: $662-$738) respectively. In subgroups analyses, the highest 10 years CVD risk subgroup had ICERs of $2033, $7322 and -$6000/QALY.
Interpretation: A FDC pill produced at CES costs is cost-neutral in HIC. Governments of LMI and UMI countries should assess these results based on the ICER threshold accepted in their own country and own specific health care priorities but should consider prioritizing this strategy for patients with high 10 years CVD risk as a first step.
Funding: Population Health Research Institute.
Competing Interests: AL, WT, PJ, PG, RM, GR, PL-J, PP, AA, AD and HG have no conflicts to declare. MDH reports Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events outside the submitted work from PwC Switzerland. Support for attending meetings and/or travel outside the submitted work from the World Heart Federation. MDH has an appointment at The George Institute for Global Health, which has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines and has patents pending for Heart Failure polypills. DX reports grants from Population Health Research Institute, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Coca-Cola India, the Indian Council of Medical Research, Pfizer, UK Medical Research Council, and Wellcome Trust outside the submitted work. Speaker's fees from Eli Lilly, Sanofi and Intas outside the submitted work. Support for attending meetings and/or travel outside the submitted work from the Indian Council of Medical Research, Eli Lilly, Sanofi, BIRAC and DBC. DX is an honorary VP with SOCHARA and honorary executive committee member of ISCR. SY reports grants from AstraZeneca, and Cadila Pharmaceuticals related to conducting the HOPE-3 or TIPS-3 studies and Honoraria for lectures on the Prevention of Cardiovascular Disease from diverse sources.
(© 2024 The Author(s).)
References: Cureus. 2023 Oct 14;15(10):e47032. (PMID: 38022292)
J Tehran Heart Cent. 2023 Apr;18(2):94-101. (PMID: 37637281)
Stat Med. 2011 Aug 30;30(19):2409-21. (PMID: 21611958)
Eur Heart J. 2022 Jun 1;43(21):2023-2033. (PMID: 35048107)
Lancet. 2019 Aug 24;394(10199):672-683. (PMID: 31448738)
Stat Med. 2000 May 15;19(9):1141-64. (PMID: 10797513)
Heart. 2017 Apr;103(7):483-491. (PMID: 28077465)
PLoS One. 2022 Jul 28;17(7):e0271908. (PMID: 35901100)
Lancet. 2021 Sep 25;398(10306):1133-1146. (PMID: 34469765)
Lancet. 2002 Jul 6;360(9326):2-3. (PMID: 12114031)
Eur Heart J Qual Care Clin Outcomes. 2019 Jul 1;5(3):266-271. (PMID: 30657891)
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25. (PMID: 28527533)
N Engl J Med. 2022 Sep 15;387(11):967-977. (PMID: 36018037)
Circulation. 2008 Feb 12;117(6):743-53. (PMID: 18212285)
Am Heart J. 2018 Dec;206:72-79. (PMID: 30342297)
N Engl J Med. 2016 May 26;374(21):2032-43. (PMID: 27039945)
Bull World Health Organ. 2015 Feb 1;93(2):118-24. (PMID: 25883405)
Int J Health Policy Manag. 2021 Nov 01;10(11):673-677. (PMID: 33619929)
N Engl J Med. 2016 May 26;374(21):2021-31. (PMID: 27040132)
Circ Res. 2017 Sep 1;121(6):677-694. (PMID: 28860318)
Eur Heart J Qual Care Clin Outcomes. 2022 Nov 17;8(8):899-908. (PMID: 34962984)
J Health Serv Res Policy. 1998 Oct;3(4):233-45. (PMID: 10187204)
BMC Med Res Methodol. 2013 Dec 07;13:152. (PMID: 24314264)
Vaccine. 2022 Jun 15;40(27):3802-3811. (PMID: 35606237)
J Am Coll Cardiol. 2014 Jun 3;63(21):2304-22. (PMID: 24681044)
PLoS One. 2017 Sep 5;12(9):e0182625. (PMID: 28873416)
N Engl J Med. 2016 May 26;374(21):2009-20. (PMID: 27041480)
Med Care. 2005 Mar;43(3):203-20. (PMID: 15725977)
Value Health. 2016 Dec;19(8):929-935. (PMID: 27987642)
BMJ. 2003 Jun 28;326(7404):1419. (PMID: 12829553)
Lancet Glob Health. 2023 Jun;11(6):e833-e842. (PMID: 37202020)
Appl Health Econ Health Policy. 2024 May;22(3):415-426. (PMID: 38198103)
N Engl J Med. 2021 Jan 21;384(3):216-228. (PMID: 33186492)
فهرسة مساهمة: Keywords: Cardiovascular disease; Cost implications; Cost-effectiveness; Fixed dose combination; Polypill; Primary prevention
تواريخ الأحداث: Date Created: 20240606 Latest Revision: 20240607
رمز التحديث: 20240607
مُعرف محوري في PubMed: PMC11152900
DOI: 10.1016/j.eclinm.2024.102651
PMID: 38841710
قاعدة البيانات: MEDLINE
الوصف
تدمد:2589-5370
DOI:10.1016/j.eclinm.2024.102651